After years of talks, Korea's Celltrion Group is finally moving ahead with the merger of three key affiliates aimed at improving cost competitiveness and securing investment resources, as well as simplifying transaction structures and improving governance.

After years of talks, Korea's Celltrion Group is finally moving ahead with the merger of three key affiliates aimed at improving cost competitiveness and securing investment resources, as well as simplifying transaction structures and improving governance.

As Stelara biosimilars wait in the wings, proposed legislation in the US could ease the path to commercialization. The Draft Red Tape Elimination Act aims to remove a requirement for switching studies. Opposition to the bill is expected, but if passed how much will the Act move the biosimilars needle in the country?

Marketing applications for MenABCWY, zolbetuximab, crovalimab, macitentan/tadalafil, Coacillium, mRNA-1345, dasiglucagon and ustekinumab have been submitted to the European Medicines Agency for review.